LUPIN Stock View

Lupin Ltd

₹ 1,171.25

icon 34.65 | 3.06
Market Cap ₹( Cr.)
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
Proj. Revenue ( Cr.)

Stock View


Last Updated On.

The average score for Lupin Ltd stands at 8 against 6, three months back.

Lupin Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. It diabetes brands include ONDERO and ONDERO MET.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data

50 DMA(₹)
100 DMA(₹)
200 DMA(₹)
52 Weeks Range
628.10     1,184.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required